Patients with chronic kidney disease (CKD) frequently develop mineral and bone disorders and calcific cardiovascular abnormalities. Clinical management guidelines and treatment strategies are aimed at correcting serum concentrations of phosphorus, calcium and parathyroid hormone, due to an association between these analytes and vascular disease and mortality. However, randomized clinical trials have not demonstrated that treating mineral concentration abnormalities with existing treatment options lowers the risk of cardiovascular events or death.
This systemic review and meta-analysis assessed the quality of evidence in CKD patients, for the association between the serum concentrations of phosphorus, parathyroid hormone and calcium and the risks of mortality, cardiovascular mortality, and non-fatal cardiovascular events. MEDLINE, EMBASE and hand-searches yielded 327,644 adult patients from 47 cohort studies that met the inclusion criteria. Data extracted from these studies included characteristics of the study design, participants, exposures, covariates (age, race, time receiving dialysis [or duration of CKD]), cardiovascular disease and diabetes mellitus; together with relative risk (RR) of all-cause mortality, cardiovascular mortality and nonfatal cardiovascular events per 1 mg/dL (0.32 mmol/L) increase in phosphorus concentration, 100 ng/L (10.6 pmol/L) increase in parathyroid hormone (PTH) concentration and 1 mg/dL (0.25 mmol/L) increase in calcium concentration. When possible, the extracted data were summarized across studies using random-effects meta-regression.
The authors found no evidence for an association between all-cause mortality and serum concentrations of either calcium (RR per 0.25 mmol/L increase, 1.08 [95% Cl, 1.00 -1.16]) or PTH (RR per 100 ng/L increase, 1.01 [95% Cl, 1.00 -1.02]), but did find an association with higher serum concentrations of phosphorus and mortality (RR per 0.32 mmol/L increase, 1.18 [95% Cl, 1.12 -1.25]). The results presented within this systematic review and meta-analysis highlight the lack of evidence used to inform clinical decision-making and practice guidelines for targeting serum concentrations of calcium and PTH as risk factors in patients with CKD. However, there does appear to be an association between higher serum concentrations of phosphorus and mortality in the population studied.
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Clinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Kent, UK DOI: 10. 1258/acb.2011.201108 Change in follicle stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period Randolph JF, Zheng H, Sowers MR, et al. J Clin Endocrinol Metab 2011; 96:746-54 Menopausal transition (MT) is a gradual loss of competent oocytes, cumulating in a final menstrual period (FMP) as a result of progressive dysregulation of the hypothalamicpituitary-ovarian system. In previous studies it has been demonstrated that, on average, concentrations of follicle stimulating hormone (FSH) increase and oestradiol (E 2 ) decrease during MT with the midpoint of the FSH rise occurring a year before the midpoint E 2 fall. It has also been reported that women with a later FMP have a shorter MT. The aim of this paper was to determine whether patterns of change in serum E 2 and FSH concentrations across the MT were associated with age at the FMP.
Data were collected from The Study of Women's Health across the Nation (SWAN), a seven-site, multiethnic longitudinal study of MT conducted in 3302 menstruating women aged 42-52 y. At the 1996 baseline, they had an intact uterus and were not on any medication known to affect ovarian function. Annual serum collections were analysed for E 2 and FSH concentrations and patterns of change in serum E 2 and FSH were evaluated in 1215 women with natural FMP at a follow-up visit in 2006. Semiparametric stochastic and piecewise linear mixed modelling was used for this purpose. FSH was measured by chemiluminometric and E 2 by modified ACS-180 E 2 -6 immunoassays on a Bayer ACS-180 automated analyser.
Data from 9435 samples were stratified to examine the effects of obesity, smoking and ethnicity on age at FMP. The FSH concentration began to gradually increase 6.1 y before FMP with a rapid increase 2.1 y before FMP. The FSH rise was delayed by obesity to 5.5 y before FMP but was independent of smoking and ethnicity. The E 2 concentration began to decrease 2.0 y before FMP. Obesity and smoking did not affect the pattern of E 2 change, although the decrease occurred 1.3 -1.6 y earlier in Chinese and Japanese women. FSH and E 2 attained stable levels by 2.0 and 2.2 y, respectively, after FMP. Overall FSH and E 2 patterns across MT were not related to age at FMP or smoking but were related to obesity and ethnicity.
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